The study compares the efficacy of ticagrelor monotherapy after less than 1 month of dual anti-platelet therapy (DAPT) to 12-month ticagrelor-based DAPT in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with drug-eluting stent implantation. The aim is

1 views • 19 slides

Among patients with transient ischemic attack (TIA) or minor ischemic strokes, adding ticagrelor to aspirin has shown superior efficacy in preventing stroke or death, particularly in those with ipsilateral atherosclerotic stenosis. The THALES trial demonstrated that ticagrelor added to aspirin was m

0 views • 14 slides

Patients undergoing complex PCI are at high risk of ischemic events. The TWILIGHT-COMPLEX study aims to compare the safety and efficacy of ticagrelor monotherapy versus ticagrelor with aspirin in patients who completed 3 months of DAPT post-PCI. While extended DAPT may reduce ischemic events, it als

0 views • 27 slides

Pharmacodynamic effects of switching P2Y12 inhibitors from ticagrelor to clopidogrel in coronary artery disease patients were investigated in the SWAP-4 study. De-escalation between these agents is common for various reasons. The study assessed the impact of clopidogrel loading dose, maintenance dos

0 views • 11 slides